Amplia has announced that a fifth patient enrolled in the Company’s ACCENT clinical trial in pancreatic cancer has recorded a confirmed partial response, meaning a 30% or greater decrease in the overall size of tumour lesions maintained over a two-month period, and with no new tumour lesions.
A total of 50 patients are planned for the Phase 2a ACCENT trial. A minimum of six patients who record a confirmed partial or complete response are required before recruitment of the second cohort of 24 patients can begin. Only one additional confirmed response is now required to trigger the interim analysis for the first cohort in the trial.
Amplia CEO and MD Dr Chris Burns commented:
“The continued positive data from the trial is extremely gratifying and at this rate we remain confident we will reopen recruitment in early October.”
Click here to read the ASX release.
